Document is current
Any future updates will be listed below
-
Authors
Boulware, L. Ebony https://orcid.org/0000-0002-8650-4212
Ephraim, Patti L.
Ameling, Jessica
Lewis-Boyer, LaPricia
Rabb, Hamid
Greer, Raquel C.
Crews, Deidra C.
Jaar, Bernard G.
Auguste, Priscilla
Purnell, Tanjala S.
Lamprea-Monteleagre, Julio A.
Olufade, Tope
Gimenez, Luis
Cook, Courtney
Campbell, Tiffany
Woodall, Ashley
Ramamurthi, Hema
Davenport, Cleomontina A.
Choudhury, Kingshuk Roy
Weir, Matthew R.
Hanes, Donna S.
Wang, Nae-Yuh
Vilme, Helene
Powe, Neil R.
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK079682)
National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR001117)
- License Information
-
More Information
Article History
Received: 27 November 2017
Accepted: 22 April 2018
First Online: 3 May 2018
Ethics approval and consent to participate
: Informed written consent was obtained from all human subjects who participated in the study. This study was performed in accordance with the <i>Declaration of Helsinki</i>. The Johns Hopkins School of Medicine Institutional Review Board approved all protocols and consent procedures [NA_00011846]. The Duke University School of Medicine Institutional Review Board approved all data analysis procedures [Pro00053328].
: Dr. Weir reports personal fees from Relypsa, personal fees from ZS Pharma, during the conduct of the study; personal fees from Akebia, personal fees from Janssen, personal fees from AstraZeneca, personal fees from Amgen, personal fees from MSD, personal fees from AbbVie, personal fees from Novartis, personal fees from Boston Scientific, personal fees from Sandoz, outside the submitted work.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
